Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in ...
Oncology Nurse Advisor

Cribriform Prostate Cancer Has Higher Risk of Metastasis, Might Benefit From RT

Using PROTECT trial data, investigators assessed the possible benefit of early treatment vs active monitoring for cribriform-positive prostate cancer.

Jaypirca® (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, Now Available in Canada for Adult Patients with Relapsed or Refractory Mantle Cell ...

Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available for use as monotherapy for the treatment of adult patients in Canada with: ...